Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Mizoram appoints Youth for Action as the Interfacing Agency for implementing the ABDM Microsite in Aizawl
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
With India supplying around 60% of the world's vaccine needs and 20-22% of generic exports, the country is dedicated to providing affordable, high-quality drugs and contribute to global accessibility
Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting
Subscribe To Our Newsletter & Stay Updated